Chronic obliterating diseases of the arteries of the lower extremities. Modern outpatient treatment
https://doi.org/10.17238/2072-3180-2022-43-51
Abstract
Chronic arterial occlusive disease of the lower extremities (CAODLE) account for up to 20% of the total volume of cardiovascular pathology. The human and economic costs of this disease are very high.
The main principle of the treatment of Chronic arterial occlusive disease of the lower extremities is the continuity and use of all available pharmacological and non-pharmacological methods of treatment, which are aimed at reducing the risk of developing any complication from the cardiovascular system, progression of lower limb ischemia, as well as eliminating its clinical manifestations – intermittent lameness. Thanks to modern and affordable diagnostic methods, such as ultrasound duplex vascular scanning (USDS), there are more and more opportunities for early detection of asymptomatic course of obliterating atherosclerosis of the lower extremities. For patients with CAODLE, long-term antiplatelet therapy, smoking cessation, lipid-lowering therapy, as well as diabetes and hypertension therapy are recommended. The article shows that in the world evidence base there is more and more data on the effective use of statins, cilostosal and combined antiplatelet and antithrombotic therapy after surgical treatment. The introduction of these treatments remains a challenge due to the high cost and burden of polypragmasia and requires further research.
Keywords
Supporting agencies: The study was carried out as part of the project of the Department of Health of the city of Moscow "Scientific laboratory" Moscow polyclinic "".
About the Author
A. I. Grigorieva
State Budgetary Healthcare Institution ”City Polyclinic No 107 of Moscow City Health Department”
Russian Federation
Russian Federation
Grigorieva Anna Ivanovna – Candidate of Medical Sciences, surgeon
24 Dekabristov str., Moscow, 127273
References
1. Gorokhovsky, S. Yu. The effectiveness of endovascular correction of severe degrees of chronic obliterating diseases of the lower extremities with multilevel lesions. Problems of health and ecology, 2020, № 1(63), pp. 14–20. (In Russ.)
2. Dunaevskaya S.S. Vinnik Yu.S. Development of endothelial dysfunction in obliterating atherosclerosis of the vessels of the lower extremities and markers for predicting the course of the disease. Bulletin of Siberian Medicine, 2017, № 16(1), pp. 108–118. (In Russ.)
3. Ivanoshchuk D.E., Shakhtschneider E.V. Modern view on the issues of atherosclerosis. Review of the materials of the 84th Congress of the European Society of Atherosclerosis. Atherosclerosis, 2016. № 12(3), pp. 78–84. (In Russ.)
4. Karpov Yu.A. Atherosclerosis of the arteries of the lower extremities: issues of therapeutic management. Atmosphere. Cardiology News, 2021, № 1, рр. 45–53.
5. Katelnitsky I.I., Zorkin A.A., Drozhzhin E.V., etc. The possibilities and own experience of using rivaroxaban in the complex treatment of patients with the syndrome of critical ischemia of the lower extremities. RMJ, 2018, № 6(II), pp. 85–88. (In Russ.)
6. Katelnitsky I.I., Katelnitsky I.I., Livadnyaya E.S., Bozhko A.V. Inpatient replacement technologies in the treatment of patients with ulcerative-necrotic changes in critical lower limb ischemia. Modern problems of Science and education, 2019, № 4. (In Russ.)
7. Kovalenko V.I., Temerezov T.H. et al. Hybrid surgery in the treatment of patients with obliterating atherosclerosis of the arteries of the lower extremities (literature review). Translational Medicine, 2020, № 7(1), pp. 33–38. (In Russ.)
8. Kuznetsov M.R., Reshetov I.V., Sapelkin S.V., Yasnopolskaya N.V. Conservative treatment of patients with intermittent claudication. Russian Medical Journal. Medical Review, 2021, Vol. 5, № 4, pp. 212–217. (In Russ.)
9. Morozov A.M., Akhmedova D.V., Ponomareva I.V., Peltikhina O.V. Rational choice of methods of examination of obliterating atherosclerosis of the vessels of the lower extremities. Youth and medical science. Articles of the VI All-Russian Interuniversity Scientific and Practical Conference of Young Scientists with International participation, 2019. (In Russ.)
10. Porshneva E.V., Nikiforova L.V. Povarova V.O. Efficacy of cilostazol in patients with intermittent claudication. Science of the Young, 2022, Vol. 10, № 2, рр. 175–186. (In Russ.)
11. Savina N.M. The effectiveness of rivaroxaban in reducing the risk of cardiovascular complications in patients with coronary heart disease and peripheral artery disease: the results of the COMPASS study. Cardiology, 2018, № 58(3), pp. 94–100. (In Russ.)
12. Temrezov M.B., Kovalenko V.I., Temerezov T.H. et al. Hybrid surgery in the treatment of patients with obliterating atherosclerosis of the arteries of the lower extremities (literature review). Translational Medicine, 2020, № 7(1), pp. 33–38. https://doi.org/10.18705/2311-4495-2020-7-1-33-38 (in Russ.)
13. Shabunin A.V., Matveev D.V., Kuznetsov M.R., Matveev A.D. Conservative treatment of chronic lower limb ischemia in the practice of an outpatient surgeon. Surgery. Journal named after N.I. Pirogov, 2019, № 3, pp. 98–104. (In Russ.)
14. Aboyans V, Ricco J.B., Bartelink MEL, et al. 2017 ESC guidelines on the diagnosis and treatment of peripheral arterial diseases, in collaboration with the European Society for Vascular Surgery (ESVS). document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteries Endorsed by: the European Stroke Organization (ESO) The Task Force for the Diagnosis and Treatment of Peripheral Arterial Diseases of the European Society of Cardiology (ESC) and of the European Society for Vascular Surgery (ESVS). Eur. Heart. J., 2018, № 39, pp. 763– 816.
15. Anand S.S., Bosch J., Eikelboom J.W., et al. Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial. Lancet, 2018, № 391, pp. 219–229.
16. Brown T., Forster R.B., Cleanthis M., Mikhailidis D.P., Stansby G., Stewart M. Cilostazol for intermittent claudication. Cochrane Database Syst Rev., 2021, № 6, CD003748. https://doi.org/10.1002/14651858.CD003748 pub5, PMID:34192807
17. Campia U., Gerhard-Herman M., Piazza G., Goldhaber S. Z. Peripheral Artery Disease: Past, Present, and Future. Am. J. Med., 2019, Oct, № 132(10), pp. 1133–1141. https://doi.org/10.1016/j.amjmed.2019.04.043 Epub 2019 May 29.
18. Corrado E., Mignano A.., Coppola G.. Use of statins in patients with peripheral artery disease. Trends Cardiovasc. Med., 2020, № 30(5), pp. 257–262. https://doi.org/10.1016/j.tcm.2019.07.002 Epub 2019 Jul 8.
19. Creager M. A., Bonaca M. P. Pathology of arterial disease in limb loss. J. Am. Coll. Cardiol., 2018, Oct, № 72 (18), pp. 2164–2165.
20. Debus E.S., Nehler M.R., Govsyeyev N., Bauersachs R.M., Anand S.S., Patel M.R., Fanelli F., Capell W.H., Brackin T., Hinterreiter F., Krievins D., Nault P., Piffaretti G., Svetlikov A., Jaeger N., Hess C.N., Sillesen H.H., Conte M., Mills J., Muehlhofer E., Haskell L.P., Berkowitz S.D., Hiatt W.R., Bonaca M.P. Effect of Rivaroxaban and Aspirin in patients with peripheral artery disease undergoing surgical revascularization: Insights from the VOYAGER PAD Trial. Circulation, 2021, № 5;144(14), pp1104–1116.
21. Di Minno G., Spadarella G., Cafaro G., Petitto M., Lupoli R., Di Minno A, de Gaetano G, Tremoli E. Systematic reviews and meta-analyses for more profitable strategies in peripheral artery disease. Ann Med., 2014, Nov; № 46(7), pp. 475–489. https://doi.org/10.3109/07853890.2014.932618.
22. Dittman J. M., Amendola M. F., Lavingia K. S.. Medical optimization of the peripheral artery disease patient. Seminars in Vascular Surgery, 2022, № 35(2), pp. 113–123. https://doi.org/10.1053/j.semvascsurg.2022.04.003
23. Dua A., Gologorsky R., Savage D., Rens N. et al. National assessment of availability, awareness, and utilization of supervised exercise therapy for peripheral artery disease patients with intermittent claudication. Journal of Vascular Surgery, 2020, Vol. 71, № 5, pp. 1702–1707.
24. Farhan S., Kamran H., Birgit Vogel , Karan Garg, Ajit Rao, Navneet Narula, Glenn Jacobowitz, Arthur Tarricone, Vishal Kapur. Considerations for patients with peripheral artery disease during the COVID-19 pandemic. Clin. Appl. Thromb. Hemost., 2021, Jan-Dec, № 27, рр. 1076029620986877
25. Firnhaber J. M., Powell. C. S. Lower extremity peripheral artery disease: diagnosis and treatment. Am. Fam. Physician, 2019, № 15; 99(6), pp. 362–369.
26. Hogan S.E., Nehler M.R., Anand S., Patel M.R., Debus S., Jackson M.T., Buchanan C., King R.W., Hess C., Muehlhofer E., Haskell L.P., Bauersachs R.M., Berkowitz S.D., Hsia J., Bonaca M.P. Improvement in walking impairment following surgical and endovascular revascularization: Insights from VOYAGER PAD. Vasc Med., 2022 Aug; № 27(4), рр. 343–349. https://doi.org/10.1177/1358863X221085606 Epub 2022 Apr 25.
27. Jansen-Chaparro S., López-Carmona M. D., Cobos-Palacios L. et al. Statins and peripheral arterial disease: a narrative review. Front. Cardiovasc. Med., 2021, Vol.8, art. 777016. https://doi.org/10.3389/fcvm.2021.777016.
28. Lu Gao, Wei Zhao, Qi Liu, Mingzhao Qin.. Association between metabolic syndrome and peripheral arterial disease in elderly patients with type 2 diabetes. Diabetes Metab Syndr Obes., 2021, Dec 14; № 14, pp. 4783– 4789. https://doi.org/10.2147/DMSO.S343441.eCollection2021.
29. Martinez-Singh K., Chandra V. How to build a limb salvage program. Seminars in Vascular Surgery, 2022, Vol. 35(2), pp. 228–233. https://doi.org/10.1053/j.semvascsurg.2022.04.011
30. McDermott M. M. Reducing disability in peripheral artery disease: the role of revascularization and supervised exercise therapy. Cardiovasc. Interv., 2019, Jun 24; № 12(12), pp. 1137–1139. https://doi.org/10.1016/j.jcin.2019.03.017
31. McDivitt J.D., Braun M., Kassop D. Cardiovascular Disease: Lower extremity peripheral artery disease. FP Essent., 2019, Apr, № 479, pp. 11–15.
32. Miranda J. A., Chung J., Mills .J. L. Influence of the COVID-19 pandemic on the management of chronic limb-threatening ischemia. Sem. Vasc. S., 2021), № 34, pp. 89–95.
33. Narula N., Dannenberg A.J., Olin J.W., et al. Pathology of peripheral artery disease in patients with critical limb ischemia. J. Am. Coll. Cardiol., 2018, № 72, pp. 2152–63.
34. Natale F, Capasso R, Casalino A, et al. Peripheral artery disease and abdominal aortic aneurysm: the forgotten diseases in COVID-19 pandemic. Results from an Observational Study on Real-World Management. Medicina (Kaunas), 2021, Jun 29; № 57(7), pp. 672.
35. Onuegbu A., Roy S., Budoff M. Editorial commentary: Peripheral arterial disease and statin therapy, what do we know after all these years? Trends in Cardiovascular Medicine, 2020, Vol. 30, № 5, pp. 263–264.
36. Paisley M. J., AdkarBrian S., Sheehan M., Stern J. R.. Aortoiliac occlusive disease. Seminars in Vascular Surgery, 2022, Vol. 35, № 2, pp. 162– 171.
37. Peters F., Kuchenbecker J., Kreutzburg T., Marschall U., Debus E. S., Behrendt C.-A. Long-Term effectiveness and safety of initiating statin therapy after index revascularization in patients with peripheral arterial occlusive disease. J Am Heart Assoc., 2020, Nov, № 17; 9(22), р. 018338. https://doi.org/10.1161/JAHA.120.018338 Epub 2020 Nov 13.
38. Polonsky T. S, McDermott M. M. Lower extremity peripheral artery disease without chronic limb-threatening ischemia: A Review. JAMA, 2021, Jun 1; № 325(21), pp. 2188–2198. https://doi.org/10.1001/jama.2021.2126
39. Treat-Jacobson D., Mary M., McDermott, et al. Optimal exercise programs for patients with peripheral artery disease: a scientific statement from the American Heart Association. Circulation, 2019, № 139, pp. 10–33.
Review
For citations:
Grigorieva A.I. Chronic obliterating diseases of the arteries of the lower extremities. Modern outpatient treatment. Moscow Surgical Journal. 2022;(5):43-51. (In Russ.) https://doi.org/10.17238/2072-3180-2022-43-51
Views:
577
Email this article 